Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, indicating challenges in its operational performance while also highlighting ongoing efforts to expand its market presence both domestically and internationally [2][10]. Group 1: Financial Performance - For the first half of 2025, the company's revenue was 260.34 million yuan, a decrease of 26.36% year-on-year [2][10]. - The net profit attributable to shareholders was -40.77 million yuan, representing a year-on-year decline of 820.03% [2][10]. - The gross profit margin was reported at 62.39% [10]. Group 2: Market Expansion and Strategy - The company has been focusing on expanding its overseas market presence, achieving product approvals and market penetration in multiple countries [3][6]. - In the domestic market, the company is targeting high-end products for tertiary hospitals while also developing the county-level market through training and promotional events [5][6]. Group 3: Competitive Landscape - The soft endoscope industry is characterized by high market share held by foreign companies, particularly in tertiary hospitals, indicating significant potential for domestic alternatives [4]. - The company is actively pursuing technological innovation and product iteration to enhance its competitiveness and recognition in clinical settings [4]. Group 4: Future Outlook - The company aims to optimize its operational rhythm and product layout to support sustainable growth, with a vision to become a globally influential endoscope brand [9]. - There is an increasing demand for soft endoscope equipment driven by clinical needs and rising health awareness among residents, suggesting a positive long-term market outlook [7].